Darnitsa has suspended production of hydroxychloroquine for the treatment of COVID-19
The pharmaceutical company “Darnitsa” has suspended a project to produce the drug hydroxychloroquine for the treatment of COVID-19.
This was reported by the company’s press service.
“Darnitsa scientists closely monitor renowned medical research and take into account world scientific opinion, since patient safety and scientific feasibility are top priorities for the company. Therefore, the company has suspended the project of production of hydroxychloroquine for the treatment of COVID-19 “, says the report.
It should be noted that, if necessary, Darnitsa is ready to release this drug for patients with rheumatoid arthritis and systemic lupus erythematosus.
See also: Stepanov has indicated if the Ministry of Health plans to change the treatment protocols for COVID-19
Scientists have reported an increase in the number of deaths among COVID-19 hospital patients who took hydroxychloroquine and chloroquine. The World Health Organization has suspended testing for these drugs.
According to Worldometer, as of mid-day May 28 worldwide, the total number of confirmed cases of COVID-19 is 5,813,300, of which 357,896 are fatal, 2,515,006 people have recovered.
See also: France bans the use of hydroxychloroquine against COVID-19
In Ukraine, 22,382 cases of COVID-19 have been laboratory confirmed. For one day – 477 new cases. A total of 8,439 people have recovered in Ukraine, 669 fatal cases.
According to the materials: ukrinform.ru